|
Saturday, 24 September 2011 00:51 |
 The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of 33 cents ($0.33) per share on the $0.10 par value Common Stock of the corporation.
|
|
Read more...
|
|
Friday, 23 September 2011 00:49 |
 Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) ("Company") today announced that its Board of Directors has adopted a Stockholder Rights Plan (the "Plan").
|
|
Read more...
|
|
Friday, 23 September 2011 00:24 |
 Pacific Biosciences (NASDAQ: PACB), the Menlo Park, CA-based maker of a super-fast, super-cheap DNA sequencing instrument for medical, agricultural, and biofuels researchers, disclosed today that it’s laying off 130 employees, or 28 percent of its total workforce.
|
|
Read more...
|
|
Thursday, 22 September 2011 00:39 |
 Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that it has acquired worldwide exclusive rights to PI-2301, an experimental drug for multiple sclerosis, previously developed by Peptimmune Inc. PI-2301 has completed Phase 1b in multiple sclerosis and is ready to initiate phase 2 clinical trials.
|
|
Read more...
|
|
Wednesday, 21 September 2011 00:25 |
|
 The buyout firm Blackstone has teamed up with an American producer of over-the-counter products to bid for Solapdeine and a cluster of other brands being sold by GlaxoSmithKline (GSK).
|
|
Read more...
|
|
Wednesday, 21 September 2011 00:16 |
|
 Jefferies is out with its report today on Bristol-Myers Squibb (NYSE: BMY), upgrading BMY from Hold to Buy.
In its report, Jefferies writes, "Two very positive things have happened. Firstly Yervoy has got off to a spectacular launch during Q2'11.
|
|
Read more...
|
|
Tuesday, 20 September 2011 00:25 |
|
 Watson Pharmaceuticals Inc., the generic-drug maker, will pay $79 million and Novartis AG’s Sandoz unit will pay $66 million to resolve claims they defrauded U.S. and state governments by causing Medicaid to overpay for drugs.
|
|
Read more...
|
|
Monday, 19 September 2011 00:18 |
|
 Tyco International Ltd. (NYSE: TYC) announced today that it has reached an agreement to acquire Visonic Ltd. (TASE: VSC.TA), a global developer and manufacturer of electronic security systems and components, for approximately $100 million in cash.
|
|
Read more...
|
|
Monday, 19 September 2011 00:06 |
 Just about all the major pharmaceutical companies have their own venture capital funds to invest in biotech startups, and now one of the real biggies, Whitehouse Station, NJ-based Merck, has joined the club.
|
|
Read more...
|
|
Saturday, 17 September 2011 00:48 |
|
Immune Response BioPharma, Inc. today September 14, 2011 announced that it plans to offer $100 million aggregate principal amount of 10% Equity Units in a proposed private offering to “Accredited Investors” and “qualified institutional buyers,” as defined in Rule 144A under the Securities Act of 1933, as amended, and non-U.S. persons outside the United States under Regulation S under the Securities Act of 1933. The Equity Units offer expires 08/02/2012.
|
|
Read more...
|
|
|
Saturday, 24 September 2011 00:43 |
 MWI Veterinary Supply, Inc. ("MWI" or "the Company") (NASDAQ: MWIV) announced today that it has entered into a definitive agreement to acquire substantially all of the assets of Micro Beef Technologies, Ltd. ("Micro") for approximately $60 million, including approximately $53.4 million in cash and common stock valued at $6.6 million.
|
|
Read more...
|
|
Friday, 23 September 2011 00:48 |
|
Ariel Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on the development and commercialization of products for acute central nervous system (CNS) diseases and trauma, announced today that it has in-licensed its lead product, AP-1531, for the treatment of acute migraine attacks, from the specialist healthcare company BTG International Ltd (LSE: BGC).
|
|
Read more...
|
|
Thursday, 22 September 2011 00:43 |
 Alkermes plc (NASDAQ:ALKS - News) and Elan Corporation, plc (NYSE:ELN - News) (“Elan”) today announced the completion of the merger between Alkermes, Inc. and Elan Drug Technologies (EDT), the drug formulation and manufacturing business unit of Elan, following the approval of the merger by Alkermes, Inc. shareholders on Sept. 8, 2011.
|
|
Read more...
|
|
Thursday, 22 September 2011 00:32 |
 Moberg Derma AB (STO:MOB.st - News)(OMX: MOB) and Meda AB have entered into a license agreement covering rights for Nalox® - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.
|
|
Read more...
|
|
Wednesday, 21 September 2011 00:20 |
 KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”), a privately-held biotechnology company focused on the development and commercialization of products in aesthetic medicine, today announced the closing of a $37.4M Series D financing.
|
|
Read more...
|
|
Tuesday, 20 September 2011 00:36 |
 Southwest Research Institute was awarded a $4.4 million contract from the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority to develop a nasal-delivery, first-line treatment system to combat cyanide poisoning.
|
|
Read more...
|
|
Tuesday, 20 September 2011 00:21 |
 Immunotec Inc. (TSX-V: IMM.V - News), a Canadian based company and a leader in the wellness industry (the "Company"), today announces the closing of a financing with TD Bank Group for the sum of $3, 450,000.
|
|
Read more...
|
|
Monday, 19 September 2011 00:11 |
 During an investor presentation the other day, Novartis execs spent considerable time not only discussing recent financial performance and pipeline progress, but also the many steps taken to save money. These include a raft of cuts across various divisions around the globe and, in the US, consolidating some operations, such as shifting some research from Boston to New Jersey.
|
|
Read more...
|
|
Saturday, 17 September 2011 00:52 |
|
 DiscoveryBioMed, Inc. (DBM), a human cell-based drug discovery company, learned recently that its Cystic Fibrosis Corrector Ligand (CFCL) Drug Discovery program will be funded by the NIH.
|
|
Read more...
|
|
Saturday, 17 September 2011 00:38 |
|
 For its first five years, VentiRx Pharmaceuticals had an unusual setup in which it was based in two places, with a drug development team in Seattle, and the business and administrative operation in San Diego. Now it’s all being merged together in Seattle, as the company looks to conserve cash and concentrate its efforts on doing one thing well—cancer drug development.
|
|
Read more...
|
|
